$1.03
+0.02 (+1.98%)
Open$1.02
Previous Close$1.01
Day High$1.05
Day Low$1.00
52W High$4.19
52W Low$0.81
Volume—
Avg Volume100.4K
Market Cap11.97M
P/E Ratio—
EPS$-1.39
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,066.0% upside
Current
$1.03
$1.03
Target
$32.61
$32.61
$25.28
$32.61 avg
$46.79
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 2.43M | 2.52M | 2.31M |
| Net Income | 150.5K | 215.1K | 194.2K |
| Profit Margin | 6.2% | 8.5% | 8.4% |
| EBITDA | 295.2K | 302.7K | 296.9K |
| Free Cash Flow | 147.2K | 165.8K | 140.8K |
| Rev Growth | +21.7% | -7.9% | -0.3% |
| Debt/Equity | 0.76 | 0.80 | 0.85 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |